HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
4.030
-0.010 (-0.25%)
At close: Oct 6, 2025, 4:00 PM EDT
4.030
0.00 (0.00%)
Pre-market: Oct 7, 2025, 4:23 AM EDT
HCW Biologics Employees
HCW Biologics had 36 employees as of December 31, 2024. The number of employees decreased by 9 or -20.00% compared to the previous year.
Employees
36
Change (1Y)
-9
Growth (1Y)
-20.00%
Revenue / Employee
$23,134
Profits / Employee
-$598,721
Market Cap
8.67M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36 | -9 | -20.00% |
| Dec 31, 2023 | 45 | 1 | 2.27% |
| Dec 31, 2022 | 44 | 0 | - |
| Dec 31, 2021 | 44 | 4 | 10.00% |
| Dec 31, 2020 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
HCWB News
- 6 days ago - HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program - GlobeNewsWire
- 18 days ago - HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing - GlobeNewsWire
- 20 days ago - HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development - GlobeNewsWire
- 6 weeks ago - HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform - Benzinga
- 6 weeks ago - HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market - GlobeNewsWire
- 7 weeks ago - HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 3 months ago - HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors - GlobeNewsWire
- 3 months ago - HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements - GlobeNewsWire